Carisma Therapeutics Inc. Increase (Decrease) in Accounts Receivable
Carisma Therapeutics Inc. reported Increase (Decrease) in Accounts Receivable of -$21.01 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-02-28
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was $2.00K, a 99.99% decline year-over-year.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2022-09-30 was -$73.00K.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2022-06-30 was -$939.00K.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was -$20.00M, a 793.00% decline year-over-year.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$21.01M, a 185.78% decline from fiscal 2021.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2021 was $24.49M.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2020 was $0.00.
- Carisma Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2019 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2022-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$71.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.01M derived: sum of 3 quarters · filed 2023-02-28 | -$21.01M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$73.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-07 | -$1.01M derived: sum of 2 quarters · filed 2022-11-07 | -$21.01M 10-Q · filed 2022-11-07 | $2.37M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | -$939.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-25 | -$20.94M 10-Q/A · filed 2022-08-25 | $2.45M derived: sum of 3 quarters · filed 2023-02-28 | $1.25M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | -$20.00M 10-Q · filed 2022-05-09 | $3.39M derived: sum of 2 quarters · filed 2023-02-28 | $2.19M derived: sum of 3 quarters · filed 2023-02-28 | $1.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | $23.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $22.19M derived: sum of 2 quarters · filed 2023-02-28 | $21.61M derived: sum of 3 quarters · filed 2023-02-28 | $24.49M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-07 | -$1.78M derived: sum of 2 quarters · filed 2022-11-07 | $1.11M 10-Q · filed 2022-11-07 | $1.11M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$583.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-25 | $2.30M 10-Q/A · filed 2022-08-25 | $2.30M derived: sum of 3 quarters · filed 2023-02-28 | $2.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.89M 10-Q · filed 2022-05-09 | $2.89M derived: sum of 2 quarters · filed 2023-02-28 | $2.89M derived: sum of 3 quarters · filed 2023-02-28 | $2.89M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |